Connection

Andrew Ward to Humans

This is a "connection" page, showing publications Andrew Ward has written about Humans.
Connection Strength

0.141
  1. Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. Sci Adv. 2021 07; 7(31).
    View in: PubMed
    Score: 0.008
  2. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020 11 27; 370(6520):1089-1094.
    View in: PubMed
    Score: 0.007
  3. Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex. Acta Crystallogr F Struct Biol Commun. 2019 May 01; 75(Pt 5):340-347.
    View in: PubMed
    Score: 0.007
  4. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep. 2018 10 24; 8(1):15701.
    View in: PubMed
    Score: 0.006
  5. The 2017 Keystone Symposium on HIV Vaccines. Hum Vaccin Immunother. 2017 10 03; 13(10):2348-2351.
    View in: PubMed
    Score: 0.006
  6. Time-course, negative-stain electron microscopy-based analysis for investigating protein-protein interactions at the single-molecule level. J Biol Chem. 2017 11 24; 292(47):19400-19410.
    View in: PubMed
    Score: 0.006
  7. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic ß-Hairpin Structure. Immunity. 2017 04 18; 46(4):690-702.
    View in: PubMed
    Score: 0.006
  8. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol Rev. 2017 01; 275(1):21-32.
    View in: PubMed
    Score: 0.006
  9. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016 Mar 03; 531(7592):118-21.
    View in: PubMed
    Score: 0.005
  10. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner. mBio. 2021 08 31; 12(4):e0100221.
    View in: PubMed
    Score: 0.002
  11. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 2021 07 13; 36(2):109353.
    View in: PubMed
    Score: 0.002
  12. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021 08 13; 373(6556):818-823.
    View in: PubMed
    Score: 0.002
  13. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021 05 19; 12(1):2938.
    View in: PubMed
    Score: 0.002
  14. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021 05 12; 29(5):806-818.e6.
    View in: PubMed
    Score: 0.002
  15. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021 04 01; 184(7):1821-1835.e16.
    View in: PubMed
    Score: 0.002
  16. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. PLoS Pathog. 2021 02; 17(2):e1009282.
    View in: PubMed
    Score: 0.002
  17. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 2020 12; 16(12):e1009089.
    View in: PubMed
    Score: 0.002
  18. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020 12 15; 53(6):1272-1280.e5.
    View in: PubMed
    Score: 0.002
  19. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Rep. 2020 10 20; 33(3):108274.
    View in: PubMed
    Score: 0.002
  20. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020 11 12; 183(4):1043-1057.e15.
    View in: PubMed
    Score: 0.002
  21. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020 08 07; 369(6504):643-650.
    View in: PubMed
    Score: 0.002
  22. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat Commun. 2020 05 27; 11(1):2688.
    View in: PubMed
    Score: 0.002
  23. Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Cell Rep. 2019 09 24; 28(13):3395-3405.e6.
    View in: PubMed
    Score: 0.002
  24. Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor. Molecules. 2019 Apr 22; 24(8).
    View in: PubMed
    Score: 0.002
  25. Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. J Pharm Sci. 2019 07; 108(7):2264-2277.
    View in: PubMed
    Score: 0.002
  26. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 11 22; 218(suppl_5):S612-S626.
    View in: PubMed
    Score: 0.002
  27. HIV-1 vaccine design through minimizing envelope metastability. Sci Adv. 2018 11; 4(11):eaau6769.
    View in: PubMed
    Score: 0.002
  28. OSCA/TMEM63 are an Evolutionarily Conserved Family of Mechanically Activated Ion Channels. Elife. 2018 11 01; 7.
    View in: PubMed
    Score: 0.002
  29. Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. Nat Commun. 2018 09 12; 9(1):3693.
    View in: PubMed
    Score: 0.002
  30. Structure of the human volume regulated anion channel. Elife. 2018 08 10; 7.
    View in: PubMed
    Score: 0.002
  31. Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. Immunity. 2018 08 21; 49(2):288-300.e8.
    View in: PubMed
    Score: 0.002
  32. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity. 2018 08 21; 49(2):363-374.e10.
    View in: PubMed
    Score: 0.002
  33. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun. 2018 07 10; 9(1):2669.
    View in: PubMed
    Score: 0.002
  34. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.002
  35. Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. Front Immunol. 2018; 9:1116.
    View in: PubMed
    Score: 0.002
  36. Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. Nat Commun. 2018 05 16; 9(1):1956.
    View in: PubMed
    Score: 0.002
  37. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS Pathog. 2018 05; 14(5):e1006986.
    View in: PubMed
    Score: 0.002
  38. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat Microbiol. 2018 06; 3(6):670-677.
    View in: PubMed
    Score: 0.002
  39. Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell Rep. 2018 04 03; 23(1):90-99.
    View in: PubMed
    Score: 0.002
  40. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. Nat Commun. 2018 02 28; 9(1):877.
    View in: PubMed
    Score: 0.002
  41. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response. Vaccine. 2018 03 14; 36(12):1627-1636.
    View in: PubMed
    Score: 0.002
  42. Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. J Biol Chem. 2018 02 02; 293(5):1688-1701.
    View in: PubMed
    Score: 0.001
  43. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat Commun. 2017 11 21; 8(1):1655.
    View in: PubMed
    Score: 0.001
  44. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A. 2017 11 28; 114(48):E10438-E10445.
    View in: PubMed
    Score: 0.001
  45. High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. J Virol. 2017 11 15; 91(22).
    View in: PubMed
    Score: 0.001
  46. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. J Virol. 2017 11 01; 91(21).
    View in: PubMed
    Score: 0.001
  47. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell Rep. 2017 Oct 03; 21(1):222-235.
    View in: PubMed
    Score: 0.001
  48. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med. 2017 Sep 04; 214(9):2573-2590.
    View in: PubMed
    Score: 0.001
  49. Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. Sci Rep. 2017 08 21; 7(1):8390.
    View in: PubMed
    Score: 0.001
  50. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017 08 29; 114(35):E7348-E7357.
    View in: PubMed
    Score: 0.001
  51. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. J Biol Chem. 2017 09 22; 292(38):15849-15858.
    View in: PubMed
    Score: 0.001
  52. Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. J Virol. 2017 08 01; 91(15).
    View in: PubMed
    Score: 0.001
  53. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity. 2017 06 20; 46(6):1073-1088.e6.
    View in: PubMed
    Score: 0.001
  54. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. J Virol. 2017 06 15; 91(12).
    View in: PubMed
    Score: 0.001
  55. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell. 2017 May 18; 169(5):878-890.e15.
    View in: PubMed
    Score: 0.001
  56. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity. 2017 05 16; 46(5):777-791.e10.
    View in: PubMed
    Score: 0.001
  57. Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein. Immunity. 2017 05 16; 46(5):792-803.e3.
    View in: PubMed
    Score: 0.001
  58. In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. Nat Commun. 2017 05 15; 8:15371.
    View in: PubMed
    Score: 0.001
  59. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Rep. 2017 04 11; 19(2):413-424.
    View in: PubMed
    Score: 0.001
  60. Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein. J Biol Chem. 2017 05 19; 292(20):8236-8243.
    View in: PubMed
    Score: 0.001
  61. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0.001
  62. A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. Science. 2014 Feb 07; 343(6171):656-661.
    View in: PubMed
    Score: 0.001
  63. Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. Cell Rep. 2013 Dec 12; 5(5):1443-55.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.